Medi-Exametazime

Tc-MR-14

Indications
After radiolabelling with sodium pertechnetate (99mTc) solution, the solution obtained is indicated for

Neurology:

  • Evaluation of patients with cerebrovascular disease (specifically acute stroke, chronic ischemia, and transient ischemic attack)
  • Presurgical lateralization and localization of epileptogenic foci.
  • Evaluation of patients with suspected dementia (specifically Alzheimer’s disease and frontotemporal dementia)
  • Adjuvant technique in the diagnosis of brain death.

Infectious or inflammatory diseases:

  • Detection of sites of focal infection (e.g. abdominal abscess),
  • Investigation of pyrexia of unknown origin,
  • Evaluation of inflammatory conditions not associated with infection such as inflammatory bowel disease.

Labelling activity
0.37-2.2 GBq (10-60 mCi)

Shelf life
12 months

Shelf-life and storage conditions after radiolabelling
60 minutes, Do not store above 25°C. Do not refrigerate or freeze after radiolabelling.

Medi-RadioPharma is a long-established producer and distributor of radiopharmaceuticals, sealed radiation sources, and calibration standards for nuclear medicine, research, and industrial applications. With a portfolio covering diagnostic and therapeutic isotopes, generators, and custom-made radioactive preparations, Medi-RadioPharma serves hospitals, laboratories, and industrial partners across international markets.

Through its partnership with Van Overeem Nuclear B.V., Medi-RadioPharma enhances its service offering: Van Overeem’s Sources Made Easy concept provides customers with convenient multi-annual agreements for the delivery of new sources and the safe disposal of depleted ones, fully tailored to departmental needs.

Together, Medi-RadioPharma and Van Overeem Nuclear B.V. deliver a comprehensive, reliable solution for isotope supply, logistics, and lifecycle management — ensuring high-quality, compliant support for medical imaging, therapy, research, and industrial processes.